Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

(10) Goodwill and Other Intangible Assets

Most of the Company's goodwill is related to the Sanuk reportable segment, with the remaining related to the UGG and other brands reportable segments. The Company's goodwill and other intangible assets are summarized as follows:



	Gross Carrying Amount			Weighted- Average Amortization Period	Accumulated Amortization		Net Carrying Amount
As of December 31, 2013
Intangibles subject to amortization	$	101,963		14 years	$	24,140	$	77,823
Intangibles not subject to amortization:
Goodwill							128,725
Trademarks							15,455
Total goodwill and other intangible assets							$	222,003
As of December 31, 2012
Intangibles subject to amortization	$	96,674	*	14 years	$	16,164	$	80,510	*
Intangibles not subject to amortization:
Goodwill							128,725		*
Trademarks							15,455
Total goodwill and other intangible assets							$	224,690

Changes in the Company's goodwill are summarized as follows:



	Goodwill, Gross			Accumulated Impairment			Goodwill, Net
Balance at January 1, 2012	$	135,876		$	(15,831	)	$	120,045
Additions through acquisitions	8,680		*	—			8,680		*
Impairment loss	—			—			—
Balance at December 31, 2012	$	144,556	*	$	(15,831	)	$	128,725	*
Additions through acquisitions	—			—			—
Impairment loss	—			—			—
Balance at December 31, 2013	$	144,556		$	(15,831	)	$	128,725

The additions to goodwill through acquisitions were attributable to the other brands reportable segments (see Note 8).

As of December 31, 2013 and 2012, the Company performed its annual impairment tests and evaluated its UGG and other brands' goodwill. As of October 31, 2013 and 2012, the Company performed its annual impairment tests and evaluated its Teva trademarks and Sanuk goodwill. Based on the carrying amounts of the UGG, Teva, Sanuk, and other brands' goodwill, trademarks, and net assets, the brands' 2013 and 2012 sales and operating results, and the brands' long-term forecasts of sales and operating results as of their evaluation dates, the Company concluded that the carrying amounts of the UGG, Sanuk and other brands' goodwill, as well as the Teva trademarks, were not impaired. The Sanuk brand goodwill was evaluated based on qualitative analyses as of October 31, 2012 and based on Level 3 inputs as of October 31, 2013. As of December 31, 2013 and 2012, and as of October 31, 2013 and 2012, all goodwill other than the Sanuk brand goodwill and all other nonamortizable intangibles were evaluated based on qualitative analyses.

As of December 31, 2013 and 2012, total goodwill by segment is as follows:



	As of December 31,
	2013		2012
UGG brand	$	6,101	$	6,101
Sanuk brand	113,944		113,944
Other brands	8,680		8,680		*
Total	$	128,725	$	128,725	*

*The above tables, as well as the Consolidated Balance Sheet at December 31, 2012, have been retrospectively adjusted to reflect adjustments to the purchase price allocation from our prior year acquisition. Goodwill was increased and other intangible assets were decreased by $2,458. The adjustments to amortization expense as a result of these changes was immaterial.

Aggregate amortization expense for amortizable intangible assets for the years ended December 31, 2013, 2012 and 2011, was $7,975, $9,312 and $9,599, respectively. The following table summarizes the expected amortization expense on existing intangible assets, excluding indefinite-lived intangible assets of $10,237, for the next five years:



Year ending December 31
2014	$	7,524
2015	7,024
2016	5,789
2017	5,620
2018	5,620
Thereafter	36,009
	$	67,586

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details